ACADIA Financial Statements From 2010 to 2025

ACAD Stock  USD 20.04  0.00  0.00%   
ACADIA Pharmaceuticals financial statements provide useful quarterly and yearly information to potential ACADIA Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on ACADIA Pharmaceuticals financial statements helps investors assess ACADIA Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting ACADIA Pharmaceuticals' valuation are summarized below:
Gross Profit
582 M
Profit Margin
0.1383
Market Capitalization
3.3 B
Enterprise Value Revenue
3.0332
Revenue
929.2 M
There are over one hundred nineteen available fundamental measures for ACADIA Pharmaceuticals, which can be analyzed over time and compared to other ratios. Investors should ensure to validate all of ACADIA Pharmaceuticals' latest performance against the performance from 2010 to 2025 to make sure the company is sustainable in the coming quarters. The current year's Market Cap is expected to grow to about 1.9 B. The current year's Enterprise Value is expected to grow to about 1.8 B

ACADIA Pharmaceuticals Total Revenue

877.17 Million

Check ACADIA Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ACADIA Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 8 M, Selling General Administrative of 474.6 M or Total Revenue of 877.2 M, as well as many indicators such as Price To Sales Ratio of 6.04, Dividend Yield of 0.0 or PTB Ratio of 11.23. ACADIA financial statements analysis is a perfect complement when working with ACADIA Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of ACADIA Pharmaceuticals Correlation against competitors.
For information on how to trade ACADIA Stock refer to our How to Trade ACADIA Stock guide.

ACADIA Pharmaceuticals Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets904.4 M861.3 M485.3 M
Slightly volatile
Short and Long Term Debt Total69.1 M65.8 M25.7 M
Slightly volatile
Common Stock Shares Outstanding197.8 M188.4 M120.9 M
Slightly volatile
Liabilities And Stockholders Equity904.4 M861.3 M485.3 M
Slightly volatile
Non Current Liabilities Total76 M72.4 M26.5 M
Slightly volatile
Total Liabilities383 M364.8 M121.2 M
Slightly volatile
Other Current Liabilities272.6 M259.6 M80.1 M
Slightly volatile
Total Current Liabilities307 M292.4 M91.9 M
Slightly volatile
Property Plant And Equipment Net68.2 M64.9 M25.1 M
Slightly volatile
Current Deferred Revenue1.3 M1.4 M1.4 M
Slightly volatile
Accounts Payable21.2 M20.2 M7.4 M
Slightly volatile
Cash227.8 M217 M126.5 M
Slightly volatile
Non Current Assets Total160.4 M152.8 M46.4 M
Slightly volatile
Cash And Short Term Investments269.3 M504.7 M356.2 M
Slightly volatile
Common Stock Total Equity19.3 K18.4 K12.3 K
Slightly volatile
Short Term Investments185.1 M287.7 M238.6 M
Slightly volatile
Other Current Assets47.2 M45 M16.6 M
Slightly volatile
Property Plant And Equipment Gross79.7 M75.9 M27.1 M
Slightly volatile
Total Current Assets744 M708.5 M437.8 M
Slightly volatile
Short Term Debt11.4 M10.8 M5.3 M
Slightly volatile
Common Stock19.3 K18.4 K12.3 K
Slightly volatile
Property Plant Equipment74.4 M70.8 M22.6 M
Slightly volatile
Other Liabilities11 M10.4 M3.8 M
Slightly volatile
Net Tangible Assets403.1 M460.5 M355.3 M
Slightly volatile
Capital Surpluse1.6 B3.1 B1.6 B
Slightly volatile
Warrants14.1 M15.9 M17.3 M
Slightly volatile
Net Receivables123.6 M117.7 M38.8 M
Slightly volatile
Non Current Liabilities Other12.7 M17.4 M7.7 M
Slightly volatile
Net Invested Capital401.6 M388.6 M415.7 M
Slightly volatile
Net Working Capital383.3 M325.7 M395.9 M
Slightly volatile
Long Term InvestmentsM2.6 M1.7 M
Slightly volatile
Capital Stock17.1 K18.4 K15 K
Slightly volatile
Capital Lease Obligations50.5 M65.8 M27.1 M
Slightly volatile

ACADIA Pharmaceuticals Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative474.6 M452 M228.8 M
Slightly volatile
Total Revenue877.2 M835.4 M287.5 M
Slightly volatile
Other Operating Expenses965.8 M919.8 M433.6 M
Slightly volatile
Research Development424.6 M404.4 M186.5 M
Slightly volatile
Total Operating Expenses910.6 M867.2 M417.4 M
Slightly volatile
Depreciation And Amortization6.7 M6.4 M2.5 M
Slightly volatile
Cost Of Revenue25.4 M41.2 M25.4 M
Very volatile
Tax Provision12.4 M11.8 M2.8 M
Slightly volatile
Interest Income20.8 M19.8 M6.1 M
Slightly volatile
Net Interest Income20.8 M19.8 MM
Slightly volatile
Selling And Marketing Expenses10.3 M10.8 M14.6 M
Slightly volatile
Reconciled Depreciation3.5 M6.4 M3.2 M
Slightly volatile

ACADIA Pharmaceuticals Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
End Period Cash Flow227.8 M217 M128.3 M
Slightly volatile
Begin Period Cash Flow76.1 M132.1 M101.9 M
Slightly volatile
Depreciation6.7 M6.4 M2.5 M
Slightly volatile
Total Cash From Financing Activities27.5 M28.9 M117.4 M
Pretty Stable
Stock Based Compensation56.8 M59.8 M194.7 M
Slightly volatile
Sale Purchase Of Stock19.8 M20.9 M116.3 M
Pretty Stable
Change To Netincome56.3 M71.2 M50.3 M
Slightly volatile
Issuance Of Capital Stock21.5 M22.6 M206.8 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio6.046.355.4 K
Pretty Stable
Days Sales Outstanding56.1859.141.6 K
Slightly volatile
Stock Based Compensation To Revenue0.09990.1182.2212
Slightly volatile
Capex To Depreciation6.826.493.0999
Slightly volatile
EV To Sales5.886.195.3 K
Pretty Stable
Inventory Turnover2.541.471.8025
Slightly volatile
Days Of Inventory On Hand154257252
Slightly volatile
Payables Turnover2.853.013.3841
Slightly volatile
Sales General And Administrative To Revenue0.460.49112
Pretty Stable
Research And Ddevelopement To Revenue0.410.44110
Pretty Stable
Capex To Revenue0.04710.04962.3747
Pretty Stable
Cash Per Share4.083.083.3912
Very volatile
Days Payables Outstanding113126124
Slightly volatile
Intangibles To Total Assets0.08260.07870.0336
Slightly volatile
Current Ratio2.072.189.1544
Slightly volatile
Receivables Turnover4.636.394.3364
Slightly volatile
Graham Number5.155.4212.0678
Slightly volatile
Capex Per Share0.30.280.0956
Slightly volatile
Average Receivables48.8 M57.8 M58 M
Very volatile
Revenue Per Share5.355.12.0826
Slightly volatile
Interest Debt Per Share0.380.40.4964
Slightly volatile
Debt To Assets0.08270.08780.0453
Slightly volatile
Operating Cycle3693881.7 K
Slightly volatile
Days Of Payables Outstanding113126124
Slightly volatile
Ebt Per Ebit1.060.80.9596
Slightly volatile
Quick Ratio1.952.059.0934
Slightly volatile
Net Income Per E B T0.821.081.009
Very volatile
Cash Ratio0.630.672.4653
Slightly volatile
Days Of Inventory Outstanding154257252
Slightly volatile
Days Of Sales Outstanding56.1859.141.6 K
Slightly volatile
Fixed Asset Turnover15.9311.5821.6318
Pretty Stable
Debt Ratio0.08270.08780.0453
Slightly volatile
Price Sales Ratio6.046.355.4 K
Pretty Stable
Asset Turnover0.920.870.3963
Slightly volatile

ACADIA Pharmaceuticals Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.9 B1.8 B1.7 B
Slightly volatile
Enterprise Value1.8 B1.7 B1.6 B
Slightly volatile

ACADIA Fundamental Market Drivers

Forward Price Earnings27.8552
Cash And Short Term Investments438.9 M

ACADIA Upcoming Events

26th of February 2024
Upcoming Quarterly Report
View
13th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
26th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About ACADIA Pharmaceuticals Financial Statements

ACADIA Pharmaceuticals stakeholders use historical fundamental indicators, such as ACADIA Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Although ACADIA Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in ACADIA Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on ACADIA Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in ACADIA Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue1.4 M1.3 M
Total Revenue835.4 M877.2 M
Cost Of Revenue41.2 M25.4 M
Stock Based Compensation To Revenue 0.11  0.10 
Sales General And Administrative To Revenue 0.49  0.46 
Research And Ddevelopement To Revenue 0.44  0.41 
Capex To Revenue 0.05  0.05 
Revenue Per Share 5.10  5.35 
Ebit Per Revenue(0.10)(0.12)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether ACADIA Pharmaceuticals is a strong investment it is important to analyze ACADIA Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact ACADIA Pharmaceuticals' future performance. For an informed investment choice regarding ACADIA Stock, refer to the following important reports:
Check out the analysis of ACADIA Pharmaceuticals Correlation against competitors.
For information on how to trade ACADIA Stock refer to our How to Trade ACADIA Stock guide.
You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ACADIA Pharmaceuticals. If investors know ACADIA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ACADIA Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
28.347
Earnings Share
0.78
Revenue Per Share
5.622
Quarterly Revenue Growth
0.183
Return On Assets
0.0872
The market value of ACADIA Pharmaceuticals is measured differently than its book value, which is the value of ACADIA that is recorded on the company's balance sheet. Investors also form their own opinion of ACADIA Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is ACADIA Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ACADIA Pharmaceuticals' market value can be influenced by many factors that don't directly affect ACADIA Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ACADIA Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if ACADIA Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ACADIA Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.